SCHEMBL15055658

SCHEMBL15055658

CCc1ccc(S(=O)(=O)Nc2ccc(C(=O)OC)c(O)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
USP2 O75604 2/20 0.57
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57
UCHL1 P09936 1/20 0.56
MCL1 Q07820 1/20 0.53
MAPT P10636 5/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
POLB P06746 1/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
FFAR4 Q5NUL3 1/20 0.50
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TP53 P04637 2/20 0.49
GHSR Q92847 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15055358 0.91 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1USP2HPGD
SCHEMBL15055973 0.89 FFAR1 (0.56) ALDH1A1KMT2AMEN1USP2HPGD
SCHEMBL9997902 0.88 ALDH1A1 (0.81) ALDH1A1KMT2AMEN1USP2HPGD
SCHEMBL15055801 0.87 TCF4 (0.62) ALDH1A1KMT2AMEN1HPGDMCL1
SCHEMBL15056080 0.86 ALDH1A1 (0.55) ALDH1A1HPGDMCL1HTTSMN1; SMN2
SCHEMBL15056016 0.85 SMN1; SMN2 (0.70) ALDH1A1KMT2AMEN1HPGDTSHR
SCHEMBL15056053 0.84 PTPN5 (0.66) ALDH1A1KMT2AMEN1MCL1MAPT
SCHEMBL15055884 0.84 MCL1 (0.61) ALDH1A1KMT2AMEN1MCL1MAPT
SCHEMBL15055896 0.82 MEN1 (0.54) KMT2AMEN1MCL1SMN1; SMN2GAA
SCHEMBL15055672 0.81 MCL1 (0.80) ALDH1A1MCL1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104168958-B Diaryl sulfonamides useful for the treatment of inflammation and cancer 坎塞拉有限公司 2017-12-01 CN claimed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP claimed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US claimed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 US claimed
CN-104168958-A Diaryl sulfonamides useful for the treatment of inflammation and cancer KANCERA AB 2014-11-26 CN claimed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 EP claimed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 WO claimed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 US disclosed
CN-104168958-B Diaryl sulfonamides useful for the treatment of inflammation and cancer 坎塞拉有限公司 2017-12-01 CN disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 US disclosed
CN-104168958-A Diaryl sulfonamides useful for the treatment of inflammation and cancer KANCERA AB 2014-11-26 CN disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 EP disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF ALDH1A1 1259/4885KMT2A 3118/4885MEN1 4161/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF ALDH1A1 1305/4885KMT2A 3165/4885MEN1 4261/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF ALDH1A1 1305/4885KMT2A 3165/4885MEN1 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.